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1875-9572/Copyright ª 2015, TaiwanBackground: Data on the pattern of epilepsy caused by metabolic disorders in the first 2 years
of life are limited in developing countries. We aimed to identify the metabolic causes of epi-
lepsy presented in the first 2 years of life and to describe their clinical, radiological, molecular,
and electroencephalographic characteristics.
Methods: This retrospective study was conducted between January 2010 and December 2011
at Saad Specialist Hospital (Al Khobar, Saudi Arabia). All patients younger than 2 years at
the onset of epilepsy caused by metabolic disorders were reviewed. The International League
Against Epilepsy definition was used, and febrile convulsion was excluded.
Results: Of 221 children diagnosed with epilepsy in the first 2 years of life at our hospital, 24
had metabolic diseases. The characteristics of these 24 children included the following: con-
sanguinity in 18 patients (75%), developmental delay in 13 (54%), generalized toniceclonic sei-
zures in 10 (42%), infantile spasms in four (17%), myoclonic in seven (29%), and focal seizures in
three. The diagnosis was confirmed by DNA studies in 17 patients (71%) and enzyme assay in
seven (29%). The main diagnoses were peroxisomal disorders (n Z 3), nonketotic hyperglyci-
nemia (nZ 3), Menkes disease (nZ 2), neuronal ceroid lipofuscinosis (nZ 2), biotinidase defi-
ciency (n Z 2), and mitochondrial disorder (n Z 2). The remaining patients had lysosomal
storage disease, aminoacidopathy, fatty acid oxidation defects, and organic aciduria. Seizure
freedom was achieved in one third of patients in this cohort.of Pediatrics, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
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394 S. Mohamed et alConclusion: Different metabolic disorders were identified in this cohort, which caused
different types of epilepsy, especially myoclonic seizures and infantile spasms.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The burden of epilepsy on children and their families is
heavy. This situation becomes worse when devastating
disorders such as metabolic diseases cause epilepsy. Epi-
lepsy secondary to metabolic diseases was previously clas-
sified as symptomatic epilepsy and is currently part of the
structural/metabolic group according to the recent Inter-
national League Against Epilepsy (ILAE) classification.1
Metabolic disorders are essentially caused by deficiency
of an enzyme or a cofactor. Occasionally, these disorders
are caused by a transport defect in which enzymes and
cofactors are intact.2,3 This metabolic derangement results
in toxic accumulation of substrates before the enzyme
block, defects in energy production, deficiency of products
after the block, or a combination of all these metabolic
deviations.4 The biochemical composition of brain is
distinct from that of other organs, and there is a complex
relationship between the concentration of metabolites and
neural function.5,6 Thus, the brain is often affected by
metabolic abnormalities, leading to epilepsy and other
neurologic manifestations.7,8 Some of these inborn errors of
metabolism affect the brain cells directly, causing mito-
chondrial, lysosomal, and peroxisomal disorders. Others
affect the brain indirectly by causing hypoglycemia, as in
fatty acid oxidation defects.9,10 During early life, the
immature and developing brain often exhibits a greater
sensitivity to these disorders compared with other age
groups.11,12 Epileptic seizures that are caused by inborn
errors of metabolism may be nonspecific or can often take a
typical clinical course.13,14 Occasionally, specific electro-
encephalography (EEG) features may point toward the
diagnosis early in the course of the disease.15,16 Epileptic
syndromes characterized by distinct seizure semiology and
a characteristic EEG pattern may be caused by metabolic
disorders, especially when presenting early in infancy.15,16
Although epilepsy is one of the leading chronic disorders
in children, its metabolic etiology is often difficult to
confirm and easy to miss. Therefore, we conducted this
study to identify the metabolic causes of epilepsy pre-
sented in the first 2 years of life and to describe their
clinical, radiological, molecular, and electroencephalo-
graphic characteristics.2. Methods
This was a retrospective study conducted at Saad Specialist
Hospital (Al Khobar, Saudi Arabia) from January 2010 to
December 2011. This is a large private institute with 600
beds, 100 of which are allocated to children. All pediatric
specialized services were available in this instituteincluding services for neurologic and metabolic diseases.
We reviewed all patients younger than 2 years who came to
our institute with newly diagnosed epilepsy secondary to
metabolic disorders. These patients were identified from
the medical records of pediatric neurologic and metabolic
clinics, pediatric wards, and neonatal and pediatric inten-
sive care units. Data were extracted from medical records
using a case report form. The clinical characteristics
recorded in this form included the following: demographic
information, consanguinity, age at first seizure, seizure
type, developmental milestones, abnormal clinical find-
ings, results of laboratory and radiological tests, EEG re-
ports, and final diagnosis. The results of the following tests
were also reviewed from the electronic laboratory records:
serum glucose, lactate, ammonia, and amino acids; blood
gas; acylcarnitine profile; urinary organic acids, ketones,
and reducing substances; enzyme assays; and DNA studies.
The following tests were reviewed as indicated by clinical
features: transferrin isofocusing; lactate-to-pyruvate ratio;
and skin and muscle biopsy for functional, biochemical,
enzyme, DNA, and histopathological analysis, including
electronic microscopy.
In this study, epilepsy was classified according to the
ILAE.1 The diagnosis of metabolic disorder was based on
biochemical, enzymatic, and molecular studies according
to the clinical profile of each patient. The response to
antiepileptic drugs (AEDs) was categorized into three
groups according to the presence or absence of seizure
freedom. The first group included seizure-free patients who
became and remained seizure free within 6 months of
starting AED. The AED regimen was defined as a mono-
therapy or a combination of two or more AEDs. The second
group included patients who fluctuated between a period
of seizure-free status and relapse within 6 months of
starting AED. The third group includes patients who were
never seizure free within 6 months of starting AED.
2.1. Statistical analysis
The data were analyzed using SPSS version 17 (SPSS Inc.,
Chicago, IL, USA). Mean, median, and standard deviations
were used for descriptive data.3. Results
Of the 221 children diagnosed with epilepsy presenting in
the first 2 years of life at our hospital, 24 had metabolic
diseases. The clinical characteristics (Table 1) of these 24
patients were as follows: 13 (54%) male patients, positive
family history of similar metabolic disease in a first-degree
relative in eight (34%), and consanguinity in 18 (75%). The
Table 1 Characteristics of the 24 children with epilepsy
secondary to metabolic disorders.*
Variables No. of patients (%)
Total No. 24 (100)
Sex distribution
Male 13 (54)
Female 11 (46)
Age at the onset of seizure (mo)
0e12 16 (67)
13e24 8 (33)
Age at diagnosis (mo)
0e12 10 (42)
13e24 8 (33)
25e30 6 (25)
Consanguinity
Yes 18 (75)
No 6 (25)
Family history of metabolic disease
Yes 8 (33)
No 16 (67)
Symptoms’ duration before the first seizure (wk)
<1 5 (21)
>1 19 (79)
Seizures type
Focal seizures 3 (12)
Generalized seizures
Toniceclonic 10 (42)
Myoclonic 7 (29)
Infantile spasms 4 (17)
Hypotonia 9 (38)
Developmental delay 13 (54)
Abnormal MRI findings 12 (50)
Diagnosis confirmed by
Enzyme study 7 (29)
Mutation analysis 17 (71)
MRI Z magnetic resonance imaging.
* All children were younger than 2 years.
Epilepsy in Neurometabolic Disorders 395onset of seizures was in infancy in 16 (67%) patients and in
the 2nd year of life in eight (33%) patients. The duration of
other symptoms before the first seizure occurred was 1
week in five (21%) patients and >1 week in 19 (79%) pa-
tients. Developmental delay was observed in 13 patients
(54%) and hypotonia in nine (38%) patients. The dominant
type of seizures in these patients was found to be gener-
alized toniceclonic in 10 (42%), infantile spasms (Figure 1)
in four (17%), myoclonic in seven (29%), and focal seizure in
three (12%). These types of seizures led to a variety of EEG
changes observed in our patients including generalized
spikes and waves (Figure 2), generalized slowing, focal
epileptogenic discharge, and hypsarrhythmia.
All patients were subjected to magnetic resonance im-
aging (MRI) of the brain, which revealed abnormal findings
in half of the cases (Table 2; Figures 3 and 4), including an
increased signal in cerebral white matter and basal ganglia,
brain atrophy, demyelination, and subdural effusion.
The final diagnoses (Table 2) of this cohort were
confirmed by DNA studies in 17 patients (71%) and enzyme
assay in seven (29%) patients. Confirmed diagnoses includedperoxisomal disorders (n Z 3), nonketotic hyperglycinemia
(n Z 3), Menkes disease (n Z 2), neuronal ceroid lip-
ofuscinosis (n Z 2), biotinidase deficiency (n Z 2), mito-
chondrial disorder (n Z 2), short-chain acyl-coenzyme A
(CoA) dehydrogenase deficiency (n Z 2), very-long-chain
acyl-CoA dehydrogenase deficiency (VLCAD; n Z 1), carni-
tine acylcarnitine translocase deficiency (n Z 1), carnitine
palmitoyltransferase type II (n Z 1), phenylketonuria
(n Z 1), glutaric aciduria type I (n Z 1), citrullinemia
(n Z 1), congenital disorder of glycosylation type 1c
(n Z 1), NiemannePick disease type C (n Z 1), and
Sandhoff disease (n Z 1).
Seizure freedom was achieved in eight patients with
fatty acid oxidation disorders, phenylketonuria, cit-
rullinemia, and biotinidase deficiency. By contrast, seizure
freedom was not achieved in patients with peroxisomal
disorders, nonketotic hyperglycinemia, Menkes disease,
and neuronal ceroid lipofuscinosis (Table 2). Furthermore,
response to AED fluctuated between seizure-free periods
and relapse in patients with mitochondrial disorders, lipid
storage diseases, glutaric aciduria type I, and congenital
disorder of glycosylation.4. Discussion
Although individually rare, inherited metabolic diseases
collectively affect a significant percentage of children
presenting with acute and life-threatening conditions.2
Seizures are often caused by metabolic disturbances,
some of which are due to inborn errors of metabolism.17,18
When presenting with seizures, the diagnosis of these dis-
orders can be challenging, and therefore, a high index of
suspicion is needed to make the right diagnosis and to start
the proper management that can sometimes be life-
saving.3,4 Proper history taking, especially detailed family
history, may point toward the diagnosis of inherited
metabolic disease. Most of our patients were the product of
consanguineous marriage and one third had a history of an
affected person with the same metabolic disease in the
family. This was not surprising because the prevalence of
consanguinity in Saudi Arabia is high compared with other
countries.19 It is well-known that consanguinity increases
the risk of inherited diseases in the offspring because it
brings the recessive genes together to manifest as a disease
entity. It is interesting that a vast majority of our patients,
who had their mutations detected, showed a homozygous
mutation compared with the double heterozygous muta-
tions usually observed in other countries.2,19 This can be
explained by the fact that the community in Saudi Arabia is
mostly tribal and tends to live in clusters and practice
intermarriage, which increases the chance of individuals to
carry homozygous mutation.19
According to the clinical practice guidelines developed
by our hospital, basic metabolic screening including anal-
ysis of serum ammonia, lactate, and amino acids in addition
to urine organic acids is recommended for all infants pre-
senting with recurrent unexplained seizures. Detailed
metabolic investigations including enzymes assay and mo-
lecular studies were guided by other clinical manifestations
and the likelihood of specific metabolic disorders. This
approach is thought to be cost effective and likely to pick
Figure 1 Electroencephalogram showing hypsarrhythmia in a 9-month-old infant (patient number 4) with nonketotic
hyperglycinemia.
396 S. Mohamed et alout the relatively small number of children with metabolic
disorders among those presenting with epilepsy.3,17,18 By
implementing this diagnostic strategy, we identified a va-
riety of disorders causing seizures in young children.
The spectrum of metabolic disorders in our cohort was
wide and included peroxisomal disorders, mitochondrial
diseases, lysosomal storage diseases, organic aciduria, urea
cycle defects, and fatty acid oxidation defects. Some of
these disorders tend to affect the central nervous systemFigure 2 Electroencephalogram showing generalized spikes and
discharges in a 1-year-old (patient number 1) with peroxisomal bioprimarily and cause chronic encephalopathy, and hence,
they were more prevalent in our patients. This group
included peroxisomal biogenesis disorders, nonketotic
hyperglycinemia, neuronal ceroid lipofuscinosis, mitochon-
drial disease, and Menkes disease. Most of these metabolic
disorders present in a progressive manner with develop-
mental delay, hypotonia, and epilepsy, as observed in our
patients.5,6 The exception to this pattern of presentation is
nonketotic hyperglycinemia, which usually presents withwaves in addition to bilateral posterior quadrant epileptiform
genesis disorder.
Table 2 Clinical, laboratory, radiological, and electroencephalographic findings in the 24 children with epilepsy secondary to metabolic disorders.
Patient Metabolic disorder Clinical manifestations Type of seizures EEG Brain MRI Result of confirmatory test Response to AED
1. Peroxisomal
biogenesis disorder
(PEX19)
Hypotonia,
developmental delay,
liver dysfunction
Myoclonic Generalized spikes
and waves
Brain atrophy,
demyelination
c.320delA homozygous
mutation in the PEX gene
Never seizure free
2. Zellweger syndrome
(PEX1)
Hypotonia,
developmental delay
GTC Generalized slowing Brain atrophy c.2528 G>A homozygous
mutation in the PEX1 gene
Never seizure free
3. Zellweger syndrome
(PEX1)
Hypotonia,
developmental delay,
dysmorphism
Infantile spasm Hypsarrhythmia Brain atrophy c.2528 G>A homozygous
mutation in the PEX1 gene
Never seizure free
4. Nonketotic
hyperglycinemia
Acute encephalopathy,
hypotonia
Infantile spasm Hypsarrhythmia Brain atrophy Homozygous 50 UTR deletion
of the GLDC gene
Never seizure free
5. Nonketotic
hyperglycinemia
Acute encephalopathy,
microcephaly
Infantile spasm Hypsarrhythmia Bilateral
subcortical
heterotopia
Homozygous 50 UTR deletion
of the GLDC gene
Never seizure free
6. Nonketotic
hyperglycinemia
Hypotonia Infantile spasm Hypsarrhythmia Brain atrophy Homozygous 50 UTR deletion
of the GLDC gene
Never seizure free
7. Menkes disease Macrocephaly,
hypopigmented brittle
hair, fractures
Myoclonic Generalized slowing Bilateral
subdural
effusion
c.1933C>T hemizygous
mutation in the ATP7A gene
Never seizure free
8. Menkes disease Hypopigmented brittle
hair, hypotonia
Myoclonic Generalized slowing Normal c.1933C>T hemizygous
mutation in the ATP7 gene
Never seizure free
9. Neuronal ceroid
lipofuscinosis-2
Microcephaly,
developmental delay
Myoclonic Generalized slowing Cerebellar and
vermian
atrophy
p.G514 R; g.5837 A>T
heterozygous mutation in the
CLN2 gene
Never seizure free
10. Neuronal ceroid
lipofuscinosis-3
Developmental delay GTC Generalized slowing Increased T2
signal in
cerebral white
matter
IVS2e3C>T homozygous
mutation in the CLN3 gene
Never seizure free
11. Biotinidase deficiency Alopecia, hypopigmented
skin, developmental
regression
GTC Generalized slowing Normal p.C33F homozygous mutation
in exon 2 of the BTD gene,
also low serum biotinidase
Seizure free
12. Biotinidase deficiency Developmental delay GTC Generalized slowing Normal Low serum biotinidase Seizure free
13. Complex 1 respiratory
chain deficiency
Failure to thrive,
developmental delay,
cardiomyopathy
GTC Generalized slowing Increased signal
in basal ganglia
Low muscle NADH-Q
oxyreductase
Fluctuating seizure
free and relapse
14. Mitochondrial DNA
depletion syndrome
Hypotonia, liver failure Focal Focal temporoparietal
epileptogenic discharge
Normal c.766_767insGATT insertion
homoplasmy mutation in the
DGUOK gene
Fluctuating seizure
free and relapse
15. SCAD Hypotonia,
developmental delay
GTC Generalized slowing Normal Low SCAD enzyme in skin Seizure free
16. SCAD Hypotonia,
developmental delay
GTC Generalized slowing Normal Low SCAD enzyme in skin Seizure free
(continued on next page)
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Table 2 (continued )
Patient Metabolic disorder Clinical manifestations Type of seizures EEG Brain MRI Result of confirmatory test Response to AED
17. Phenylketonuria Microcephaly,
craniosynostosis, features
of AntleyeBixler
syndrome
GTC Generalized slowing Normal p.R261 homozygous mutation
in exon 7 of PAH
Seizure free
18. Glutaric aciduria type
1
Developmental delay,
choreoathetosis
Myoclonic Generalized slowing
Focal temporoparietal
epileptogenic discharge
Wide Sylvian
fissures
Low glutaryl-CoA
dehydrogenase in skin
Fluctuating seizure
free and relapse
19. Citrullinemia Acute encephalopathy GTC Generalized slowing Normal p.R363W homozygous
mutation in the ASS1 gene
Seizure free
20. Congenital disorder of
glycosylation Type 1c
Developmental delay Focal Focal temporoparietal
epileptogenic discharge
Normal c.482A>G (p.Y161C)
homozygous mutation in the
ALG6-CDG gene
Fluctuating seizure
free and relapse
21. NiemannePick disease
type C
Hepatosplenomegaly,
cherry red spot
Focal Focal temporoparietal
epileptogenic discharge
Normal Low leukocyte
sphingomyelinase enzyme
Fluctuating seizure
free and relapse
22. Sandhoff disease Cherry red spot,
developmental regression
Myoclonic Generalized slowing,
focal temporoparietal
epileptogenic discharge
Demyelination Low leukocyte galactosidase
A enzyme
Fluctuating seizure
free and relapse
23. Carnitine acylcarnitine
translocase deficiency
Acute encephalopathy Myoclonic Generalized slowing,
focal temporoparietal
epileptogenic discharge
Normal IVS2-10T>G homozygous
mutation in the CACT gene
Seizure free
24. VLCAD Acute encephalopathy,
hepatomegaly, raised CPK
GTC Generalized slowing Normal Intron 16 IVS 16 þ 6 GC
deletion homozygous for the
VLCAD gene
Seizure free
AED Z antiepileptic drugs; CoA Z coenzyme A; CPK Z creatinine phosphokinase; EEG Z electroencephalogram; GTC Z generalized toniceclonic; MRI Z magnetic resonance imaging;
NADHZ nicotinamide adenine dinucleotide (reduced); PEXZ peroxi; SCADZ short-chain acyl CoA dehydrogenase deficiency; UTRZ untranslated region; VLCADZ very-long-chain acyl
CoA dehydrogenase deficiency.
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Figure 3 T1-weighted brain magnetic resonance imaging of a
1-year-old child (patient number 18) with glutaric aciduria type
1 showing thick cerebral cortex with poorly developed sulcal
and gyral formation. Wide Sylvian fissure is partially visualized.
Figure 4 Brain magnetic resonance imaging of a 10-month-
old infant (patient number 10) with neuronal ceroid
lipofuscinosis-3 showing diffusely increased T2-weighted signal
in cerebral white matter bilaterally, which is more pronounced
in the posterior portions.
Epilepsy in Neurometabolic Disorders 399acute epileptic encephalopathy, as observed in three of our
patients with this disorder. This disorder often presents with
infantile spasms that are difficult to control and carry a poor
prognosis.7,20 Some of our patients presented with acute
decompensation, as in citrullinemia, due to the toxic effect
of the associated hyperammonemia. If diagnosed early, this
particular disorder is potentially treatable by detoxifying
medication and dialysis.3,4 Thus, early diagnosis and treat-
ment of the underlying metabolic derangement are likely to
prevent epilepsy in these patients. Similarly, patients with
fatty acid oxidation defects, especially those with VLCAD
and carnitine cycle disorders, develop encephalopathy and
epilepsy secondary to hypoglycemia, which cause energy
deficiency. Therefore, treating the underlying pathology of
these patients by providing optimum calories, avoiding
fasting, and supplementing them with carnitine when
needed will result in a favorable outcome.8,9 Furthermore,
patients with biotinidase deficiency can benefit from early
diagnosis and replacement therapy with oral biotin, which is
an efficient and affordable medication.4,10 The prognosis for
these patients is good if biotin replacement commences in
the neonatal period. By contrast, treatment of patients with
peroxisomal biogenesis disorders, nonketotic hyper-
glycinemia, neuronal ceroid lipofuscinosis, mitochondrial
disease, and Menkes disease is supportive, and their prog-
nosis is largely unfavorable.4,10 New treatment strategies
including enzyme replacement therapy are emerging for
other inborn errors of metabolism such as mucopoly-
saccharidoses, Gaucher disease, and Fabry disease.4 In
addition, gene therapy is a promising modality but it is still
experimental.4,10
Brain MRI is occasionally performed in children with
epilepsy. This modality can delineate the anatomical dis-
tribution of the pathological insult, as well as give a
reasonable prediction of the possible etiology. In patients
with epilepsy secondary to metabolic disorders, brain MRI
may occasionally give an insight into the possible cause and
effect of the disease.5,7 Moreover, certain metabolic dis-
orders may result in typical radiological findings such as
enlarged perisylvian fissures and subdural effusion as
observed in the patient with glutaric aciduria type 1 in this
study.8,10 Subdural effusion can also be caused by Menkes
disease as observed in one patient. This patient was
initially missed as a case of nonaccidental injury. Interest-
ingly, both diagnoses can also lead to subconjunctival
hemorrhage. In this study, 50% of patients had abnormal
brain MRI. Most of these radiological changes were
nonspecific, apart from the abnormal findings in the two
patients with Menkes disease and glutaric aciduria type 1,
which suggested the diagnosis before the molecular and
enzyme results were available.
In most cases, epilepsy secondary to inherited metabolic
disorders presents with polymorphic clinical and EEG find-
ings that are difficult to classify into a precise epileptic
syndrome.6,8
Some of these rare epileptic syndromes with specific
seizure semiology and electroclinical pattern such as
Ohtahara syndrome and early myoclonic encephalopathy
start early in the neonatal period and mimic metabolic
disorders with epilepsy. Nevertheless, no patient in this
series fitted in any of the described epilepsy syndromes.
The majority of our patients presented with generalized
400 S. Mohamed et altoniceclonic seizures with generalized slowing of EEG.
However, all three patients with nonketotic hyper-
glycinemia had infantile spasms with typical hypsar-
rhythmia. A further seven patients in this cohort, with
different metabolic disorders, had myoclonic epilepsy. It
seems that specific types of seizures, such as myoclonic
seizures, or distinctive electroencephalographic patterns,
such as burst suppression patterns as in our cohort, may
suggest an underlying metabolic disease.20e24 Similar to our
findings, previous studies indicated that early myoclonic
encephalopathy may be an early sign of metabolic dis-
ease.20e24 Therefore, the correlation between the pheno-
type, mode of presentation, and EEG recordings reminds
physicians about the importance of making an accurate
diagnosis earlier in cases with neurometabolic disorders-
related early childhood epilepsy.25 Furthermore, timing
prediction of seizures is often associated with inborn errors
of metabolism, depending on the mechanism by which
seizures are produced.13,26
Management of patients with inherited metabolic dis-
orders and seizure can be challenging. In addition to
adequate general and resuscitation care including ventila-
tion, correction of fluid and electrolyte imbalance, and
starting medications and special formula as indicated, pa-
tients with inborn errors of metabolism require early se-
lective use of antiepileptic medications if presenting with
recurrent seizures. However, some of these medications
may be harmful by, for example, increasing the risk of
hepatotoxicity in patients with mitochondrial diseases
already receiving sodium valproate.25 One third of patients
in this study achieved seizure freedom, whereas the rest
failed to achieved this or fluctuated with an occasional
relapse. Most of those who responded to AED had treatable
metabolic diseases such as citrullinemia and biotinidase
deficiency. By contrast, patients who failed to respond to
AEDs had metabolic disorders with no specific available
treatment such as peroxisomal disorders and lysosomal
storage diseases. It is worth noting that some patients may
need multiple antiepileptic medications to show clinical
response. Others may show changes in the pattern and type
of seizures during treatment.25
The introduction of the expanded newborn screening for
treatable metabolic disorders has increased the early
detection rate and improved management and outcome of
many patients.3,4 However, the management and prognosis
of some of the untreatable metabolic disorders causing epi-
lepsy, such as peroxisomal andmitochondrial disorders, have
not improved significantly in the past few decades despite
the advances in technology and diagnostic facilities.6,14
In addition to being a retrospective review, this study
has other limitations including the patient referral system,
which was based on private and insurance schemes, and
thus, may not necessarily represent the pattern of diseases
in the wider community.5. Conclusion
In this cohort of young children, different metabolic dis-
orders were identified, which caused different types of
epilepsy, especially myoclonic seizures and infantile
spasms.Conflicts of interest
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